MoonLake Immunotherapeutics MLTX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Based on trailing twelve months.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's return on equity?
- MoonLake Immunotherapeutics (MLTX) reported return on equity of -77.7% in Q1 2026.
- How has MoonLake Immunotherapeutics's return on equity changed year-over-year?
- MoonLake Immunotherapeutics's return on equity decreased by 154.3% year-over-year, from -30.6% to -77.7%.
- What is the long-term trend for MoonLake Immunotherapeutics's return on equity?
- Over 2 years (2023 to 2025), MoonLake Immunotherapeutics's return on equity has grown at a 113.9% compound annual growth rate (CAGR), from -13.2% to -60.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.